HIMS & HERS HEALTH INC (HIMS) is rated highest by Validea’s P/B Growth Investor model, based on Partha Mohanram’s strategy. The stock is a mid-cap growth stock in the Biotechnology & Drugs industry, with a rating of 77%. The strategy looks for low book-to-market stocks with sustained future growth potential. The stock meets most of the strategy’s tests, including book/market ratio, return on assets, and cash flow from operations to assets. Mohanram’s research on growth investing has shown significant market outperformance, and he is currently the John H. Watson Chair in Value Investing at the University of Toronto.

Read more at Nasdaq, Inc.: HIMS Factor-Based Stock Analysis | Nasdaq